Our present findings indicate no significant difference in eotaxin level between MM patients and controls (p = 0.60); however, patients who were primary refractory to bortezomib demonstrated a higher eotaxin level than those in early relapse. This evidence concerns the gene CCL11 and Miyoshi myopathy.